On April 28, the drug clinical trial registration and information disclosure platform showed that Hengrui Pharmaceutical (600276.SH) initiated a phase III clinical trial (CTR20241529) of HR17031 injections with randomized, open, parallel control, and treatment compliance.
The Zhitong Finance App learned that on April 28, the drug clinical trial registration and information disclosure platform showed that Hengrui Pharmaceutical (600276.SH) initiated a phase III clinical trial (CTR20241529) of the HR17031 injection with random, open, parallel control, and treatment standards. The study aimed to compare the efficacy and safety of HR17031 injection with insulin glargine in type 2 diabetics receiving metformin with or without another oral hypoglycemic agent. The main end point was the change in HbA1c relative to baseline at week 26.
According to reports, HR17031 is a fixed-ratio compound injection of basic long-acting insulin and GLP-1 analogues independently developed by Hengrui, and is intended to be used to treat type 2 diabetes. In July 2021, HR17031 was clinically approved in the US and China. Domestically, Hengrui is leading the development of similar drugs. HR17031 is the first domestically produced insulin+GLP-1 analog compound formulation to enter phase III clinical trials.
At the same time, Hengrui has carried out a multi-party layout around the GLP-1R target. In addition to HR17031, the once-daily GLP-1R agonist noligopeptide has also entered phase III clinical phase. In addition, Hengrui also has the GLP-1R/GIPR agonist HRS9531 and the small-molecule GLP-1R agonist HRS-7535, all of which have advanced to phase II clinical stage.